ozempic and other glp 1 drugs Comparing Ozempic, Wegovy GLP-1 Weight Loss Blog – Maryland

Description

Expanding the use of GLP-1 receptor agonists across obesity, cardiovascular disease, chronic kidney disease, MASH, and other metabolic disorders requires manufacturers to generate robust long-term clinical evidence for each therapeutic indication

In fact, DPP-4 inhibitors, aimed at elongating effect of endogenous incretins, are available for the treatment of type 2 diabetes though the glycemic effect of these medications are comparatively modest [24]

This work demonstrated that GLP-1RA treatment was associated with a significant 29% reduction in MALOs compared to non-use (IRR: 0.71, 95%CI: 0.57-0.88, P = 0.003) over a median follow-up of approximately 70,045 patient-years

A dose of 1.0 mg once weekly of semaglutide (maximum dose subsidised by the PBS) achieved a weight reduction of 4.3 kg compared with placebo over two years